Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab monotherapy versus two ranibizumab + verteporfin photodynamic therapy regimens for subfoveal choroidal neovascularization secondary to age-related macular degeneration
2006-004131-30Phase 2Active
- Sponsor
- Dr. Félix Armadá
- Start
- Jan 2007
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ranibizumab and verteporfin in age-related macular degeneration (AMD) (3 arms), sponsored by Dr. Félix Armadá. Primary endpoint: Mean change in best-corrected visual acuity. Started Jan 2007; status: active.
02
Drugs
ranibizumabverteporfin
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2006-004131-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004131-30.